SV Life Sciences
Venture capitalBoston
Also known as SV Life Sciences CF · SV Life Sciences Strategic Partners
Fund manager profile
SV Life Sciences is a venture fund manager based in Boston. SEC filings show 3 venture funds on record, most recently SV Life Sciences Fund IV CF, L.P. ($421.4M offering) filed March 2022.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
What they invest in
from 9 of 9 portfolio companiesHealthtech ×6Biotech ×5AI & Machine Learning ×2Deep Tech ×2Advanced Manufacturing ×1Hardware ×1Medical Devices ×1Robotics ×1
HQs:United States×6
Investments · 9 tracked
founders shown can be your intro pathBy year:2018 · 12017 · 12016 · 12014 · 12012 · 15 dated
Cerevance is a clinical-stage drug discovery and development company developing non-dopaminergic, orally-delivered therapies for brain and central nervous system disorders, including Parkinson's disease, schizophrenia, Alzheimer's disease, and ALS.
BiotechDeep TechHealthtech
Craig Thompson(Chief Executive Officer)Sagar Vaidya(Chief Medical Officer)Carrie Ann Cook(Chief Business Officer)
Co-investorsForesite CapitalGV (Google Ventures)Dementia Discovery FundDementia DiscoveryLightstone VenturesSV Health Investors+2 more
HealthtechSunnyvale, US
David Milne(Director)Thomas Afzal(Executive Officer, Director)Dan Galles(Director)Mark Brooks(Director)Richard Ferrari(Director)
BoardPeter van der Velden(Director)
Board seatDavid Milne· per SEC Form D · $1.6M raise · filed Nov 2016
Co-investorsHLM Venture PartnersLumira VenturesSV Health Investors
Asensus Surgical (formerly TransEnterix) develops robotic-assisted surgical systems and augmented intelligence technology, including reusable instruments, to give surgeons real-time information during procedures.
AI & Machine LearningHealthtechMedical DevicesRoboticsMorrisville, US
Anthony Fernando(Executive Officer)Todd M Pope(Executive Officer, Director)Joseph P Slattery(Executive Officer)John Onopchenko(Director)Todd M. Pope(Executive Officer, Director)William N. Starling(Director)
Board seatDavid B Milne· per SEC Form D · $950K raise · filed Sep 2017
Co-investorsAisling CapitalSV Health InvestorsQuaker BioVentures
Adimab operates a yeast-based antibody discovery and engineering platform that produces fully human antibodies, heavy-chain antibodies, and multispecifics (including T-cell engagers) for biopharma partners.
AI & Machine LearningBiotechDeep Tech
Co-investorsGrandBanks CapitalLaunchCapitalLux CapitalPremji InvestSV Health InvestorsMithril Capital Management+1 more
Advanced ManufacturingBiotechHardwareLebanon, US
Tillman Gerngross(Director)Warren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Isett(Executive Officer, Director)Jonathan Sheller(Executive Officer)Errik Anderson(Director)
Co-investorsOrbiMedSV Health InvestorsMithril Capital ManagementSands Capital Ventures
HealthtechMenlo Park, US
Lou Bock(Director)Brett Hale(Executive Officer)Casey Tansey(Director)Frank Gentile(Director)Maria Sainz(Executive Officer, Director)Eric Fain(Director)
Co-investorsArcher Capital GroupArcher Venture CapitalSV Health InvestorsNew Leaf Venture Partners
HealthtechNewark, US
John Hendrick(Executive Officer, Director)Stephen Martin(Director)William Link(Director)Ryan Schwarz(Director)Steven Waite(Director)Andy Corley(Director)
Co-investorsSV Health InvestorsMPM BioImpactOxford Finance LLCVersant Ventures
BiotechNew York, US
David Guyer(Executive Officer, Director)Glenn Sblendorio(Executive Officer, Director)Mike AtiehinDavid Redlick(Director)Keith Westby(Executive Officer)David Carroll(Executive Officer)
Co-investorsSofinnova VenturesSV Health InvestorsClarus
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)Kazuhiro Ito(Co-founder)John Murray(Co-founder)David Mantusin
Co-investorsAdjuvant CapitalF-Prime CapitalJeito CapitalLongwood FundSR One Capital ManagementSV Health Investors+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 1
IPOs and acquisitions across the tracked portfolioAvitideacq. by Repligen
Portfolio news
latest coverage across their companiesAdimab · nasdaqprivatemarket.com · Mar 2, 2025
Fund performance · per public LP disclosures
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| SV Life Sciences Fund VI, L.P.LPs: New Mexico Educational Retirement Board | 2015 | — | 14.0% | 1.58x | 1.22x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- Where is SV Life Sciences located?
- SV Life Sciences is headquartered in Boston, US.